NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM
2013 · Proceedings of the National Academy of Sciences · 110 citations
https://doi.org/10.1073/pnas.1303932110
M
Misty Dawn Shields
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
50
Papers
698
Citations
9
h-index
9
i10-index
Misty Dawn Shields is an academic researcher from ApeX Therapeutics (United States). The author has contributed to research in topics: Lung Cancer Research Studies & Lung Cancer Treatments and Mutations & Neuroendocrine Tumor Research Advances. The author has an h-index of 9, co-authored 43 publications.
ORCID: 0000-0002-7904-5062Papers by this author
worksImmune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer
2022 · Current Treatment Options in Oncology · 14 citations
https://doi.org/10.1007/s11864-022-00989-7
Evaluation of Radiation Pneumonitis in a Phase 2 Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation Therapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer
2024 · International Journal of Radiation Oncology*Biology*Physics · 6 citations
https://doi.org/10.1016/j.ijrobp.2024.09.050
Defining the needle in a haystack: A compendium of genomic, pathologic, and clinical characteristics of rare pulmonary tumors
2024 · Lung Cancer · 1 citations
https://doi.org/10.1016/j.lungcan.2024.108035
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024
2025 · Cancer · 1 citations
https://doi.org/10.1002/cncr.70060
PP01.14 Paired Sample Analyses of NSCLC After SCLC Transformation
2025 · Journal of Thoracic Oncology · 0 citations
https://doi.org/10.1016/j.jtho.2025.03.021
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat